Beam Therapeutics reported promising Phase 1/2 data for BEAM-302, demonstrating durable gene correction for AATD. See why I ...

Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $4.0, a ...

Zurcher Kantonalbank Zurich Cantonalbank raised its position in CRISPR Therapeutics AG (NASDAQ:CRSP – Free Report) by 3.0% in ...

Farther Finance Advisors LLC boosted its holdings in CRISPR Therapeutics AG (NASDAQ:CRSP – Free Report) by 34.2% in the 4th quarter, according to its most recent Form 13F filing with the Securities & ...

The latest trading session saw CRISPR Therapeutics AG (CRSP) ending at $41.17, denoting a -1.84% adjustment from its last day's close. The stock trailed the S&P 500, which registered a daily loss of 0 ...

Gene therapy pioneer Jim Wilson and researcher Kiran Musunuru are using contrasting approaches to overcome “irrational ...

A pair of privately-held developers of editing-based therapies have some successes to show for their recent efforts to ...

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Avalo Therapeutics (AVTX – Research Report) and ...

Reuters reported that President Trump’s tariffs have impacted the broader stock markets, weighing on investors’ sentiments, ...

We came across a bullish thesis on CRISPR Therapeutics AG (CRSP) on wallstreetbets Subreddit Page by MADD-Scientis. In this ...

Targeted CRISPR lipid nanoparticles eliminated 50% of tumors in mice with head and neck cancer.

We recently published a list of Ark Invest Stock Portfolio: Top 10 Stocks to Buy. In this article, we are going to take a look at where CRISPR Therapeutics AG (NASDAQ:CRSP) stands against other top ...